anti-KLK2/CD3 bispecific antibody JNJ-78278343

A T-cell-redirecting agent and humanized immunoglobulin (Ig) G1 bispecific antibody targeting both human kallikrein-2 (hK2; KLK2) expressed on tumor cells and the CD3 receptor complex expressed on T cells, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, anti-KLK2/CD3 bispecific antibody JNJ-78278343 binds to both CD3 on T cells and KLK2 on KLK2-expressing tumor cells. The resulting cross-linkage activates and redirects T cells to KLK2-expressing tumor cells. This results in T-cell-mediated lysis of KLK2-expressing tumor cells. KLK2 is overexpressed in certain tumors, including prostate adenocarcinoma.